Exchange: NASDAQ·Updated 08:18 PM EDT

NVAX News

News
all
press releases
Novavax (NVAX) Laps the Stock Market: Here's Why
In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
Zacks
More News
Novavax to Participate in September Investor Conferences
Novavax to Participate in September Investor Conferences Novavax to Participate in September Investor Conferences PR Newswire GAITHERSBURG, Md., Sept. 2, 2026 GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in...
PR Newswire
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
Novavax is rising on investors reaction to an unconfirmed rumor that Matrix-M has a favorable safety profile with self-limiting side effects.read more...
Benzinga
What's Going On With Novavax Stock?
Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot toward licensing and cost-structure optimization.read more...
Benzinga
Novavax Stock Climbs Monday: What's Going On?
Shares of Novavax are trading higher Monday, extending its 30% monthly gains on COVID-19 vaccine approvals and broader biotech strength.read more...
Benzinga
NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season.
Stocktwits
FDA Approves 3 New COVID-19 Vaccines
FDA Approves 3 New COVID-19 Vaccines Authored by Zachary Stieber via The Epoch Times, The Food and Drug Administration on Aug. 27 approved COVID-19 vaccines from Pfizer, Moderna, and Sanofi. A nurse prepares to give a COVID-19 vaccine to a child in Denver, Colo., on Nov. 3, 2021...
Zero Hedge
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season PR...
PR Newswire
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.read more...
Benzinga
Novavax Stock Rallies Tuesday: What's Happening?
Shares of Novavax are trading higher Tuesday morning as buying interest continues across late-stage vaccine developers. read more...
Benzinga

Advertisement|Remove ads.